Fresenius SE & Co KGaA (FRE.DE) Stock Price

Fresenius SE & Co KGaA Price

XETRA·CLOSED
47.38EUR+0.31 (+0.66 %)
Market closed

Revenue has compounded at 4.0% per year over the past 19 years to 22.87 B EUR. Earnings per share have grown at 0.5% per year over the last 16 years. Fresenius SE & Co KGaA's net margin stands at 5.5%, broadly stable from 4.9% several years earlier. Fresenius SE & Co KGaA currently offers a dividend yield of about 2.11%. The payout ratio is around 45% of earnings. Analysts set a median price target of 57.12 EUR, implying 20.6% above the current price. Of 23 analysts, 21 rate the stock a buy — an overall Buy consensus. The stock trades about 34% above its 52-week low.

Fresenius SE & Co KGaA stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Fresenius SE & Co KGaA over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Fresenius SE & Co KGaA stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Fresenius SE & Co KGaA's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Fresenius SE & Co KGaA Stock Price History
DateFresenius SE & Co KGaA Price
8/11/202647.38 EUR
8/10/202647.07 EUR
8/7/202647.06 EUR
8/6/202646.68 EUR
8/5/202646.65 EUR
8/4/202644.44 EUR
7/31/202644.52 EUR
7/30/202644.54 EUR
7/29/202644.52 EUR
7/28/202644.02 EUR
7/27/202644.25 EUR
7/24/202643.80 EUR
7/23/202643.21 EUR
7/22/202643.57 EUR
7/21/202644.00 EUR
7/20/202643.00 EUR
7/17/202641.64 EUR
7/16/202641.83 EUR
7/15/202641.77 EUR
7/14/202641.02 EUR
7/13/202641.96 EUR
7/10/202642.57 EUR
7/9/202642.22 EUR
7/8/202642.73 EUR
7/7/202643.41 EUR
7/6/202643.20 EUR
7/3/202642.36 EUR
7/2/202642.12 EUR
7/1/202641.03 EUR
6/30/202639.97 EUR
6/29/202639.44 EUR
6/26/202639.82 EUR
6/25/202640.11 EUR
6/24/202640.07 EUR
6/23/202639.90 EUR
6/22/202639.54 EUR
6/19/202639.88 EUR
6/18/202638.89 EUR
6/17/202638.58 EUR
6/16/202638.57 EUR
6/15/202638.54 EUR
6/12/202637.93 EUR
6/11/202637.54 EUR
6/10/202637.67 EUR
6/9/202637.17 EUR
6/8/202637.10 EUR
6/5/202637.15 EUR
6/4/202636.61 EUR
6/3/202635.28 EUR
6/2/202635.27 EUR
6/1/202635.92 EUR
5/29/202636.98 EUR
5/28/202636.25 EUR
5/27/202637.70 EUR
5/26/202638.12 EUR
5/25/202638.46 EUR
5/22/202639.04 EUR
5/21/202640.32 EUR
5/20/202639.71 EUR
5/19/202639.65 EUR
5/18/202639.21 EUR
5/15/202638.80 EUR
5/14/202638.86 EUR
5/13/202638.33 EUR
5/12/202639.52 EUR
5/11/202639.88 EUR
5/8/202640.96 EUR
5/7/202640.74 EUR
5/6/202639.89 EUR
5/5/202639.44 EUR
5/4/202640.81 EUR
4/30/202641.25 EUR
4/29/202641.40 EUR
4/28/202640.79 EUR
4/27/202640.32 EUR
4/24/202640.25 EUR
4/23/202640.71 EUR
4/22/202642.38 EUR
4/21/202643.27 EUR
4/20/202643.78 EUR
4/17/202644.62 EUR
4/16/202644.19 EUR
4/15/202644.03 EUR
4/14/202644.85 EUR
4/13/202644.49 EUR
4/10/202644.70 EUR
4/9/202644.50 EUR
4/8/202644.75 EUR
4/7/202643.71 EUR
4/2/202643.50 EUR
3/27/202643.85 EUR
3/26/202644.00 EUR
3/24/202644.10 EUR
3/23/202643.80 EUR
3/20/202643.49 EUR
3/19/202644.64 EUR
3/17/202646.50 EUR
3/16/202647.11 EUR
3/13/202646.82 EUR
3/12/202646.89 EUR
3/11/202647.38 EUR
3/10/202648.25 EUR
3/6/202646.50 EUR
3/5/202646.64 EUR
2/27/202650.85 EUR
2/26/202651.32 EUR
2/25/202649.25 EUR
2/23/202651.93 EUR
2/20/202651.88 EUR
2/19/202652.48 EUR
2/18/202652.07 EUR
2/17/202652.01 EUR
2/16/202650.94 EUR
2/13/202650.65 EUR
2/12/202650.18 EUR
2/11/202650.09 EUR
2/10/202650.07 EUR
2/9/202649.84 EUR
2/6/202649.26 EUR
2/5/202648.63 EUR
2/4/202649.47 EUR
2/3/202648.88 EUR
2/2/202648.25 EUR
1/30/202647.10 EUR
1/29/202646.69 EUR
1/28/202647.80 EUR
1/27/202649.08 EUR
1/26/202647.92 EUR
1/23/202648.26 EUR
1/22/202648.30 EUR
1/21/202647.54 EUR
1/19/202648.98 EUR
1/17/202649.83 EUR
1/16/202650.08 EUR
1/14/202651.51 EUR
1/13/202651.18 EUR
1/12/202650.53 EUR
1/9/202649.49 EUR
1/8/202649.49 EUR
1/7/202648.50 EUR
1/6/202648.42 EUR
1/5/202647.72 EUR
1/2/202648.34 EUR
12/30/202548.85 EUR
12/29/202548.74 EUR
12/23/202548.72 EUR
12/22/202547.92 EUR
12/19/202548.08 EUR
12/18/202547.86 EUR
12/17/202547.94 EUR
12/16/202548.43 EUR
12/15/202548.46 EUR
12/12/202547.54 EUR
12/11/202547.97 EUR
12/10/202548.00 EUR
12/9/202547.07 EUR
12/8/202547.46 EUR
12/5/202547.65 EUR
12/4/202547.96 EUR
12/3/202546.88 EUR
12/2/202546.60 EUR
12/1/202546.40 EUR
11/28/202547.01 EUR
11/27/202547.41 EUR
11/26/202547.39 EUR
11/25/202547.74 EUR
11/24/202547.32 EUR
11/21/202546.48 EUR
11/20/202546.78 EUR
11/19/202547.22 EUR
11/18/202547.57 EUR
11/17/202548.92 EUR
11/14/202548.39 EUR
11/13/202549.41 EUR
11/12/202549.76 EUR
11/11/202548.89 EUR
11/10/202547.82 EUR
11/7/202547.60 EUR
11/6/202547.99 EUR
11/5/202548.13 EUR
11/4/202548.69 EUR
11/3/202549.32 EUR
10/31/202550.11 EUR
10/30/202550.84 EUR
10/29/202550.69 EUR
10/28/202549.49 EUR
10/27/202549.24 EUR
10/24/202548.78 EUR
10/23/202549.07 EUR
10/22/202547.91 EUR
10/21/202548.05 EUR
10/20/202548.03 EUR
10/17/202547.55 EUR
10/16/202546.97 EUR
10/15/202547.74 EUR
10/14/202548.77 EUR
10/13/202548.00 EUR
10/10/202547.79 EUR
10/9/202548.03 EUR
10/8/202546.59 EUR
10/7/202546.16 EUR
10/6/202546.63 EUR
10/3/202547.16 EUR
10/2/202546.71 EUR
10/1/202546.50 EUR
9/30/202547.40 EUR
9/29/202546.47 EUR
9/26/202546.35 EUR
9/25/202546.16 EUR
9/24/202546.85 EUR
9/23/202547.05 EUR
9/22/202546.66 EUR
9/19/202547.19 EUR
9/18/202547.53 EUR
9/17/202547.50 EUR
9/16/202547.11 EUR
9/15/202546.91 EUR
9/12/202546.54 EUR
9/11/202547.10 EUR
9/10/202547.26 EUR
9/9/202547.41 EUR
9/8/202547.27 EUR
9/5/202546.89 EUR
9/4/202546.95 EUR
9/3/202546.58 EUR
9/2/202546.54 EUR
9/1/202546.69 EUR
8/29/202546.53 EUR
8/28/202546.44 EUR
8/27/202546.63 EUR
8/26/202547.27 EUR
8/25/202547.38 EUR
8/22/202547.88 EUR
8/21/202547.71 EUR
8/20/202546.99 EUR
8/19/202546.84 EUR
8/18/202546.24 EUR
8/15/202546.04 EUR
8/14/202545.35 EUR
8/13/202544.93 EUR
8/12/202544.02 EUR
Access this data via the Eulerpool API
Get Free API Key

Fresenius SE & Co KGaA Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
21.07 B EUR
1.29 B EUR
-594.00 M EUR
Jan 1, 2024
21.83 B EUR
1.84 B EUR
471.00 M EUR
Jan 1, 2025
22.87 B EUR
2.50 B EUR
1.26 B EUR
Jan 1, 2026 (e)
23.69 B EUR
2.23 B EUR
2.00 B EUR
Jan 1, 2027 (e)
24.90 B EUR
2.34 B EUR
2.17 B EUR
Jan 1, 2028 (e)
26.14 B EUR
2.46 B EUR
2.40 B EUR
Jan 1, 2029 (e)
27.53 B EUR
2.59 B EUR
2.68 B EUR
Jan 1, 2030 (e)
28.96 B EUR
2.73 B EUR
2.78 B EUR

Fresenius SE & Co KGaA Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 12, 2026, 3:24 AM
 
REVENUEB EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB EUR
EBITB EUR
EBIT MARGIN%
NET INCOMEB EUR
NET INCOME GROWTH%
DIV.EUR
DIV. GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
27.6329.0833.8933.5335.4136.2837.0821.3321.0721.8322.8723.6924.9026.1427.5328.96
18.925.2716.51-1.055.602.452.21-42.47-1.233.644.763.555.134.985.325.19
30.8931.3930.9229.3329.2228.4426.4624.3823.6024.6324.8924.8924.8924.8924.8924.89
8.539.1310.489.8310.3510.329.815.204.975.385.695.906.206.516.857.21
3.884.334.593.854.634.393.602.001.291.842.502.232.342.462.592.73
14.0314.8813.5411.4913.0812.099.719.406.118.4110.929.419.419.419.419.41
1.361.591.812.031.881.711.821.37-0.590.471.262.002.172.402.682.78
27.2717.3013.8711.74-7.10-9.356.50-24.53-143.29-179.29168.3757.918.8710.3511.594.04
0.440.550.620.750.800.841.76–0.92–1.001.051.111.17––
-64.8025.0012.7320.976.675.00109.52––––5.005.715.41––
540.91546.58557.75558.67555.00554.55558.06557.55563.24563.24563.24563.24563.24563.24563.24563.24
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Fresenius SE & Co KGaA generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Fresenius SE & Co KGaA retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Fresenius SE & Co KGaA's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Fresenius SE & Co KGaA has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Fresenius SE & Co KGaA's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Fresenius SE & Co KGaA stock margins

The Fresenius SE & Co KGaA margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Fresenius SE & Co KGaA. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Fresenius SE & Co KGaA.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
26.46 %
9.71 %
4.90 %
Jan 1, 2022
24.38 %
9.40 %
6.43 %
Jan 1, 2023
23.60 %
6.11 %
-2.82 %
Jan 1, 2024
24.63 %
8.41 %
2.16 %
Jan 1, 2025
24.89 %
10.92 %
5.53 %
Jan 1, 2026 (e)
24.89 %
9.41 %
8.43 %
Jan 1, 2027 (e)
24.89 %
9.41 %
8.73 %
Jan 1, 2028 (e)
24.89 %
9.41 %
9.18 %

Fresenius SE & Co KGaA Stock Revenue, EBIT, Earnings per Share

The Fresenius SE & Co KGaA earnings per share therefore indicates how much revenue Fresenius SE & Co KGaA has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
66.44 EUR
6.45 EUR
3.26 EUR
Jan 1, 2022
38.25 EUR
3.59 EUR
2.46 EUR
Jan 1, 2023
37.40 EUR
2.29 EUR
-1.05 EUR
Jan 1, 2024
38.76 EUR
3.26 EUR
0.84 EUR
Jan 1, 2025
40.61 EUR
4.44 EUR
2.24 EUR
Jan 1, 2026 (e)
41.98 EUR
3.96 EUR
3.54 EUR
Jan 1, 2027 (e)
44.13 EUR
4.16 EUR
3.85 EUR
Jan 1, 2028 (e)
46.33 EUR
4.37 EUR
4.25 EUR

Fresenius SE & Co KGaA business model & stock analysis

Fresenius SE is a German pharmaceutical and medical technology company, which was founded in 1912 by Eduard Fresenius. The company's history is marked by continuous growth and numerous acquisitions, which have shaped the current corporate structure. Fresenius operates in four different divisions: Fresenius Medical Care is a global leader in dialysis treatment and offers products as well as services related to dialysis. Fresenius Kabi specializes in the production of medications and medical devices for infusion and nutrition therapy. Fresenius Helios is one of the largest providers of hospital treatments with over 110 clinics and operates facilities in Germany, Spain, and Latin America. Fresenius Vamed offers services related to the management and planning of healthcare facilities and operates worldwide in over 85 countries. The business model of Fresenius SE is based on the development and production of innovative medical products, as well as the provision of services in the healthcare sector. The company relies on high-quality products and intensive research and development. A key factor for success is focusing on the needs of customers and patients to ensure the best possible care. One of the most well-known products of Fresenius SE are the Fresenius concentrates for dialysis treatment. These enable effective and gentle blood cleansing, thereby improving the quality of life for dialysis patients. Another example of innovative products are the 3-in-1 infusion systems by Fresenius Kabi. These combine the administration of fluids, medications, and nutrition into one system, offering significantly higher efficiency in patient care. Fresenius Helios focuses on patient-centered care and offers a wide range of medical services. The company operates both acute care clinics and long-term care facilities and utilizes state-of-the-art technologies to improve diagnosis and treatment. Fresenius Vamed provides its customers with services such as facility management, planning, and project management for healthcare facilities, as well as operational consulting. The comprehensive expertise in all areas of the healthcare industry ensures high quality in the implementation of construction projects and renovations. In summary, Fresenius SE is an internationally active company specializing in the provision of high-quality products and services in the healthcare sector. The company focuses on patient-centered care and the continuous development of innovative products and technologies.

Fresenius SE & Co KGaA SWOT Analysis

Strengths

Fresenius SE possesses several key strengths:

  • Established presence and reputation in the healthcare industry
  • Diversified product portfolio spanning pharmaceuticals, medical devices, and services
  • Strong financial performance and stability
  • Global operations and strong market position
  • Strong research and development capabilities

Weaknesses

Despite its overall strength, Fresenius SE also faces certain weaknesses:

  • Dependency on third-party suppliers for key components
  • Regulatory challenges in different markets
  • Relatively high debt levels
  • Competitive pressures in the healthcare industry

Opportunities

Fresenius SE can capitalize on the following opportunities:

  • Increasing demand for healthcare products and services, driven by aging population and emerging markets
  • Expanding its product portfolio through strategic acquisitions and partnerships
  • Advancements in technology opening up new possibilities for product innovation
  • Expanding into underserved or untapped markets

Threats

Fresenius SE must be cautious of the following potential threats:

  • Intense competition from global and local players
  • Changing regulatory frameworks and compliance requirements
  • Volatility in raw material prices
  • Economic downturns impacting healthcare spending

Fresenius SE & Co KGaA Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Fresenius SE & Co KGaA historical P/E ratio, EBIT multiple, and P/S ratio

Fresenius SE & Co KGaA annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Fresenius SE & Co KGaA shares outstanding

The number of shares of Fresenius SE & Co KGaA was 563.24 M in 2025. This indicates how many shares Fresenius SE & Co KGaA is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
558.06 M Stocks
Jan 1, 2022
557.55 M Stocks
Jan 1, 2023
563.24 M Stocks
Jan 1, 2024
563.24 M Stocks
Jan 1, 2025
563.24 M Stocks
Jan 1, 2026 (e)
563.24 M Stocks
Jan 1, 2027 (e)
563.24 M Stocks
Jan 1, 2028 (e)
563.24 M Stocks

Fresenius SE & Co KGaA stock splits

In Fresenius SE & Co KGaA's history, there have been no stock splits.

Fresenius SE & Co KGaA Dividend History

27 years of dividend payments · 2 consecutive increases

YearAnnual DividendYoY ChangePayments
20261.05EURYTD—1×
May 25, 20261.05EUR↑ 5.0%1/1
20251.00EUR↑ 8.7%1×
May 26, 20251.00EUR↑ 8.7%1/1
20230.92EUR↑ 39.4%1×
20220.66EUR↓ 62.5%1×
20211.76EUR↑ 109.5%2×
20200.84EUR↑ 5.0%1×
20190.80EUR↑ 6.7%1×
20180.75EUR↑ 21.0%1×
20170.62EUR↑ 12.7%1×
20160.55EUR↑ 25.0%1×

Fresenius SE & Co KGaA dividend history and estimates

In 2025, Fresenius SE & Co KGaA paid a dividend amounting to 1.00 EUR. Dividend means that Fresenius SE & Co KGaA distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Special dividend
Details
Date
Dividend
Dividend (Estimate)
Special dividend
Jan 1, 2020
0.84 EUR
0.00 EUR
0.00 EUR
Jan 1, 2021
1.76 EUR
0.00 EUR
0.00 EUR
Jan 1, 2022 (e)
0.66 EUR
0.00 EUR
0.66 EUR
Jan 1, 2023
0.92 EUR
0.00 EUR
0.00 EUR
Jan 1, 2025
1.00 EUR
0.00 EUR
0.00 EUR
Jan 1, 2026
1.05 EUR
0.00 EUR
0.00 EUR
Jan 1, 2027 (e)
0.00 EUR
1.11 EUR
0.00 EUR
Jan 1, 2028 (e)
0.00 EUR
1.17 EUR
0.00 EUR

Fresenius SE & Co KGaA dividend payout ratio

In 2025, Fresenius SE & Co KGaA had a payout ratio of 44.56%. The payout ratio indicates the percentage of the company's profits that Fresenius SE & Co KGaA distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
54.03 %
Jan 1, 2022
26.82 %
Jan 1, 2023
-87.24 %
Jan 1, 2024
41.80 %
Jan 1, 2025
44.56 %
Jan 1, 2026 (e)
29.68 %
Jan 1, 2027 (e)
28.78 %
Jan 1, 2028 (e)
27.54 %

Current Fresenius SE & Co KGaA forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
91.30 % (21)
Hold
8.70 % (2)
Sell
0.00 % (0)
12M Price Target
57.12
Last Price
47.07
Currency
EUR
12M Return Potential
21.35 %
LTM Return
0 %

Fresenius SE & Co KGaA Analyst Rating Actions

DateFirmActionRatingReliability
1/2/2023
Jefferies
Jefferies
UpgradeHoldBuy47

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Fresenius SE & Co KGaA Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
2/20/20240.84EUR-7.70 BEUR-2023 Q4
11/1/20220.71EUR-10.50 BEUR-2022 Q3
7/27/20220.83EUR-10.10 BEUR-2022 Q2
5/4/20220.79EUR-9.57 BEUR-2022 Q1
2/22/20220.89EUR-10.02 BEUR-2021 Q4
11/2/20210.77EUR-9.41 BEUR-2021 Q3
7/30/20210.81EUR-9.19 BEUR-2021 Q2
5/6/20210.78EUR-9.07 BEUR-2021 Q1
2/23/20210.90EUR-9.28 BEUR-2020 Q4
10/29/20200.77EUR-9.04 BEUR-2020 Q3

EESG©

Eulerpool ESG Scorecard© for the Fresenius SE & Co KGaA stock

83/100
78
Environment
99
Social
72
Governance
E

Environment

20
Scope 1 - Direct Emissions351,128
Scope 2 - Indirect emissions from purchased energy447,563
Scope 3 - Indirect emissions within the value chain3,683,377
Total CO₂ emissions798,691
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees67.358
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Fresenius SE & Co KGaA shareholder structure

% Name
26.94983%
Else Kroner-Fresenius Foundation
Else Kroner-Fresenius Foundation
4.97276%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
3.03767%
Capital Research Global Investors
Capital Research Global Investors
2.43548%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
2.16807%
DWS Investment GmbH
DWS Investment GmbH
1.48560%
Deka Investment GmbH
Deka Investment GmbH
...

Fresenius SE & Co KGaA Beneficial Ownership Filings (SEC 13D/G)

Free Float
72.9%
Float Shares
-
Shares Outstanding
-

Fresenius SE & Co KGaA Executives and Management Board

19 members · avg. age 61 · 26 % women

PA

Mr. Pierluigi Antonelli (62)

Member of the Management Board, Chief Executive Officer - Fresenius Kabi

2.35 M EUR

Management

SH

Ms. Sara Hennicken (44)

Chief Financial Officer, Member of the Management Board

2.08 M EUR
RM

Mr. Robert Moeller (57)

Member of the Management Board, Chief Executive Officer of Fresenius Helios

1.99 M EUR
NS

Mr. Nick Stone

Senior Vice President Investor Relations, Head of Investor Relations · since 2025

–

Board of Directors

MS

Mr. Michael Sen (56)

Chairman of the Management Board

4.44 M EUR
MM

Mr. Michael Moser (49)

Member of the Management Board, Responsible for Legal, Compliance, Risk Management, ESG, Human Resources, Corporate Audit and Fresenius Vamed

1.87 M EUR
GG

Ms. Grit Genster (52)

Independent Deputy Chairman of the Supervisory Board · since 2020

310,000.00 EUR
WK

Mr. Wolfgang Kirsch (70)

Independent Chairman of the Supervisory Board · since 2021

265,000.00 EUR
BB

Mr. Bernd Behlert (66)

Independent Member of the Supervisory Board, Employee Representative

220,000.00 EUR
CZ

Dr. Christoph Zindel (63)

Independent Member of the Supervisory Board

220,000.00 EUR

Fresenius SE & Co KGaA Supply Chain

Fresenius SE & Co KGaA Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
30 companies
#Nameβ 1YTrend
1
Fresenius Medical Care
Supplier·Customer·Health Care Providers & Services·DE
0.69
0.62
0.70
0.30
0.84
0.59
0.98
2
SAP
Supplier·Software·DE
0.75
0.43
-0.21
0.53
0.70
0.56
1.13
3
RaySearch Laboratories B
Supplier·SE
-0.49
-0.67
0.11
-0.04
0.85
0.55
—
4
Aadi Biosciences
Supplier·Customer·Biotechnology·US
-0.62
0.06
-0.53
0.30
0.85
0.55
—
5
Formosa Laboratories
Supplier·Pharmaceuticals·TW
0.87
0.60
0.34
0.22
0.75
0.54
—
#Nameβ 1YTrend
1
Vocera Communications, Inc.
Supplier·Customer·Health Care Technology·US
-0.30
-0.69
0.79
-0.29
-0.77
—
—
2
Vifor Pharma
Supplier·Customer·Pharmaceuticals·CH
0.26
-0.07
0.44
-0.13
-0.69
-0.42
—
3
AbbVie
Supplier·Customer·Biotechnology·US
0.35
0.40
0.73
-0.33
-0.69
-0.38
-0.63
4
freenet AG
Supplier·Wireless Telecommunication Services·DE
-0.59
0.41
0.59
0.34
-0.71
-0.25
—
5
Elecnor
Supplier·Construction & Engineering·ES
-0.38
-0.47
0.61
-0.39
-0.40
-0.21
-0.60

Frequently asked questions about Fresenius SE & Co KGaA

Fresenius SE is a German healthcare company specializing in the provision of medical products and services. The company's business model focuses on four main segments: Fresenius Medical Care, a global leader in dialysis treatment and services; Fresenius Kabi, offering essential medicines and clinical nutrition products; Fresenius Helios, providing high-quality hospital and healthcare services; and Fresenius Vamed, specializing in projects and services for healthcare facilities. Through these segments, Fresenius SE aims to contribute to the improvement of patients' quality of life, offering comprehensive and innovative healthcare solutions worldwide.

Fresenius SE is primarily active in the healthcare industry.

The main competitors of Fresenius SE in the market include Baxter International Inc, DaVita Inc, and Cardinal Health Inc.

Fresenius SE is a prominent healthcare company with a rich history and background. Founded in 1912 by Dr. Eduard Fresenius, the company started as a pharmaceutical laboratory in Germany. Over the years, it expanded its services and is now a global leader in dialysis products, hospital equipment, and healthcare services. With a strong commitment to improve the quality of life for patients worldwide, Fresenius SE operates through its four business segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Its innovative technologies, extensive expertise, and global presence have propelled Fresenius SE to become a trusted name in the healthcare industry.

Fresenius SE, a leading healthcare company, has achieved several significant milestones throughout its history. It successfully expanded its global presence, delivering high-quality healthcare products and services to millions of patients worldwide. Fresenius SE also made notable advancements in the field of dialysis, offering innovative solutions for the treatment of chronic kidney failure. Moreover, the company has been at the forefront of pharmaceutical manufacturing and distribution, ensuring the availability of essential medications for various medical conditions. With a strong dedication to patient care and continuous innovation, Fresenius SE has consistently enhanced the quality of life for individuals around the globe.

Fresenius SE is primarily present in numerous countries and regions around the world. The company operates in various key markets, including Germany, North America, Europe, Latin America, Asia-Pacific, and Africa. With a global presence, Fresenius SE has established a strong foothold in these regions, allowing it to expand its reach and serve a diverse customer base. The company's commitment to delivering high-quality healthcare products and services has enabled it to successfully operate and thrive in these international markets.

Fresenius SE represents values of innovation, quality, and patient care in its corporate philosophy. As a leading healthcare company, Fresenius SE is committed to providing high-quality products and services for patients worldwide. It focuses on four business segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. These divisions serve different aspects of healthcare, such as dialysis, infusion therapy, hospital operations, and project development. With a strong emphasis on research and development, Fresenius SE constantly strives to improve medical treatments and enhance patient well-being. By upholding these values, Fresenius SE has become a trusted name in the healthcare industry.

Analysts currently set an average price target of 56.38 EUR for the Fresenius SE & Co KGaA stock (median: 57.12 EUR), implying +19.8 % versus the latest price. The consensus is based on 23 analyst ratings.

Fresenius SE & Co KGaA Analyst Price Targets 2026

23 analysts currently rate the Fresenius SE & Co KGaA stock: 21 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Fresenius SE & Co KGaA to generate revenue of 23.69 B EUR and earnings per share of 3.54 EUR.

Fresenius SE & Co KGaA Analyst Price Targets 2026

The Fresenius SE & Co KGaA share (FRE.DE) is listed on 10 stock exchanges, including: XETRA (FRE.DE), Frankfurt (FRE.F), München (FRE.MU), Düsseldorf (FRE.DU), Hamburg (FRE.HM), London (0OO9.L), SIX (Zürich) (FREEUR.SW), Wien (FRE.VI).

Fresenius SE is a globally leading healthcare company based in Germany. The company consists of four main business segments, including Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Fresenius Medical Care is the world's largest provider of dialysis products and services. Their portfolio includes dialysis machines, dialysis filters, and accessories, as well as innovative therapies such as hemodiafiltration and online hemodiafiltration. Additionally, Fresenius Medical Care offers comprehensive services for patients with chronic kidney diseases, including consultation, training, and support for better quality of life. Fresenius Kabi manufactures products for infusion and nutrition therapy and is a global market leader in this field. Their portfolio includes parenteral nutrition products, infusion solutions, pain therapeutics, and antibiotics. Furthermore, Fresenius Kabi provides intensified therapeutic care for patients to enable a quick recovery. Fresenius Helios is Europe's largest private hospital operator. The company operates over 100 acute clinics, rehabilitation clinics, and outpatient clinics in Germany and Spain, with a total of more than 100,000 beds. Fresenius Helios offers a wide range of medical services, including emergency care, oncology and neurology, cardiology, and orthopedics. Fresenius Vamed is an internationally active service provider for healthcare and social infrastructure. The company offers planning, construction, management, and optimization of healthcare facilities, as well as energy-efficient solutions for facility management. Fresenius Vamed also operates rehabilitation facilities, wellness facilities, and obesity centers. Fresenius SE was founded in 1912 and currently employs over 300,000 employees in over 100 countries. The company is headquartered in Bad Homburg vor der Höhe, Germany, and is listed on the Frankfurt Stock Exchange. Overall, Fresenius SE offers a wide range of products and services for all areas of healthcare, from dialysis and infusion therapy to hospital care and health infrastructure. The company is committed to improving the quality of life of their patients and ensuring high-quality medical care.

The expected revenue of Fresenius SE & Co KGaA is 23.69 B EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Fresenius SE & Co KGaA is 2.00 B EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Fresenius SE & Co KGaA is currently 13.37. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Fresenius SE & Co KGaA stock.

The price-to-sales ratio (P/S) of Fresenius SE & Co KGaA is currently 1.13. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Fresenius SE & Co KGaA stock.

The Eulerpool Quality Score for Fresenius SE & Co KGaA is 3/10.

The ISIN of Fresenius SE & Co KGaA is DE0005785604. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Fresenius SE & Co KGaA is 578560. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Fresenius SE & Co KGaA is FRE.DE. The ticker symbol is used to trade Fresenius SE & Co KGaA shares on the stock exchange.

Over the past 12 months, Fresenius SE & Co KGaA paid a dividend of 1.00 EUR . This corresponds to a dividend yield of about 2.11 %. For the coming 12 months, Fresenius SE & Co KGaA is expected to pay a dividend of 1.11 EUR.

The current dividend yield of Fresenius SE & Co KGaA is 2.11 %.

Fresenius SE & Co KGaA pays a dividend, distributed in the months of , , , .

Fresenius SE & Co KGaA paid dividends every year for the past 1 years.

For the upcoming 12 months, dividends amounting to 1.11 EUR are expected. This corresponds to a dividend yield of 2.36 %.

Fresenius SE & Co KGaA is assigned to the 'Health' sector.

To receive the latest dividend of Fresenius SE & Co KGaA from amounting to 1.05 EUR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

The dividends of Fresenius SE & Co KGaA are distributed in EUR.

All fundamentals and in-depth analysis of Fresenius SE & Co KGaA

Our stock analysis for Fresenius SE & Co KGaA stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fresenius SE & Co KGaA. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA Revenue→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA Net Income→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA P/E→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA P/S→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA EBIT→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA Dividend→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA Directors Dealings→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA Stocks→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA Market capitalization→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA Debt→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA Liabilities→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA Equity→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA AAQS→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA Employees→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA ROE→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA ROA→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA ROCE→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA News→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA Analyst Price Targets→

Health Stocks

Frontier BiotechnologiesFresenius Medical CareFuan Pharmaceutical Group CoFresenius Medical CareFuji Pharma CoFreliiFujian Cosunter Pharmaceutical CoFredun PharmaceuticalsFukuda Denshi CoFrance Bed Holdings CoFulcrum TherapeuticsForza InnovationsAll Stocks A–Z →